Cargando…
Biosimilars in rare diseases : a focus on paroxysmal nocturnal hemoglobinuria
Biologics, a class of medicines grown in and purified from genetically engineered cell cultures, have transformed the management of many cancers and rare diseases, such as paroxysmal nocturnal hemoglobinuria. As prescription drug spending has increased and exclusivity periods have expired, manufactu...
Autores principales: | Kulasekararaj, Austin, Brodsky, Robert, Kulagin, Alexander, Ho Jang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153517/ https://www.ncbi.nlm.nih.gov/pubmed/36519328 http://dx.doi.org/10.3324/haematol.2022.281562 |
Ejemplares similares
-
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria
por: Kulasekararaj, Austin G., et al.
Publicado: (2022) -
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
por: Risitano, Antonio M., et al.
Publicado: (2020) -
Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab
por: Kulasekararaj, Austin G., et al.
Publicado: (2021) -
Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment
por: Bravo-Perez, Carlos, et al.
Publicado: (2023) -
The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria
por: Lazana, Ioanna, et al.
Publicado: (2023)